

FILE COPY

Sheet 01 of 15

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT				Applicant Ashkenazi et al.	
(Use several sheets if necessary)				Filing Date 15 Sep 1999	Group 1643 1646

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
<i>ccu</i>	*	1 3,691,016	12.09.72	Patel, R.			
	*	2 3,969,287	13.07.76	Jaworek et al.			
	*	3 4,179,337	18.12.79	Davis et al.			
	*	4 4,195,128	25.03.80	Hildebrand et al.			
	*	5 4,229,537	21.10.80	Hodgins et al.			
	*	6 4,247,642	27.01.81	Hirohara et al.			
	*	7 4,301,144	17.11.81	Iwashita et al.			
	*	8 4,330,440	18.05.82	Ayers et al.			
	*	9 4,342,566	03.08.82	Theofilopoulos et al.			
	*	10 4,399,216	16.08.83	Axel et al.			
	*	11 4,419,446	06.12.83	Howley et al.			
	*	12 4,496,689	29.01.85	Mitra, G.			
	*	13 4,601,978	22.07.86	Karin, M.			
	*	14 4,640,835	03.02.87	Shimizu et al.			
	*	15 4,670,417	02.06.87	Iwasaki et al.			
	*	16 4,676,980	30.06.87	Segal et al.			
	*	17 4,736,866	12.04.88	Leder et al.			
	*	18 4,791,192	13.12.88	Nakagawa et al.			
	*	19 4,816,567	28.03.89	Cabilly et al.			
	*	20 4,855,235	08.08.89	Takahashi et al.			
	*	21 4,870,009	26.09.89	Evans et al.			
	*	22 4,965,199	23.10.90	Capon et al.			
	*	23 5,010,182	23.04.91	Brake et al.			
	*	24 5,153,118	06.10.92	Wright, Jr. et al.			
	*	25 5,158,885	27.10.92	Bradstock et al.			
<i>ccu</i>	*	26 5,364,934	15.11.94	Drayna et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes      No
<i>ccu</i>	*	27 036,776	30.09.81	EPO			
	*	28 073,657	09.03.83	EPO			
	*	29 117,058	29.08.84	EPO			
	*	30 117,060	29.08.84	EPO			
	*	31 125,023 A1	14.11.84	EPO			
	*	32 173,494	05.03.86	EPO			
	*	33 278,776	17.08.88	EPO			

Examiner

*Clara M. ke*

Date Considered

*3/12/03*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED (Use several sheets if necessary)		PATENT & TRADEMARK OFFICE JAN 27 2003 PC 37 35		Applicant Ashkenazi et al.	
				Filing Date 15 Sep 1999	Group 1643 1646

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
<i>CW</i>	* 34	307,247	15.03.89	EPO				
	* 35	321,196	21.06.89	EPO				
	* 36	362,179	04.04.90	EPO				
	* 37	417,563	20.03.91	EPO (ENGLISH ABSTRACT ATTACHED)				
	* 38	266,710	12.04.89	GERMANY (ENGLISH ABSTRACT ONLY)				
	* 39	WO 87/05330	11.09.87	PCT				
	* 40	WO 89/02922	06.04.89	PCT				
	* 41	WO 89/05859	29.06.89	PCT				
	* 42	WO 90/13646	15.11.90	PCT				
	* 43	WO 91/00358	10.01.91	PCT				
	* 44	WO 91/00360	10.01.91	PCT				
	* 45	WO 91/08291	13.06.91	PCT				
	* 46	WO 92/20373	26.11.92	PCT				
	* 47	WO 93/08829	13.05.93	PCT				
	* 48	WO 94/04679	03.03.94	PCT				
	* 49	WO 94/04690	03.03.94	PCT				
	* 50	WO 94/29348	22.12.94	PCT				
	* 51	WO 95/10540	20.04.95	PCT				
	* 52	WO 95/11301	27.04.95	PCT				
	* 53	WO 95/31544	23.11.95	PCT				
	* 54	WO 97/01633	16.01.97	PCT				
	* 55	WO 97/25428	17.07.97	PCT				
	* 56	2,211,504	05.07.89	UNITED KINGDOM				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	* 57	Adams et al., "Molecular cloning of mouse immunoglobulin heavy chain messenger ribonucleic acids coding for $\mu$ , $\alpha$ , $\gamma_1$ , $\gamma_2$ , and $\gamma_3$ chains" <u>Biochemistry</u> 19:2711-2719 (1980)
	* 58	Amakawa et al., "The Hodgkin Disease Antigen CD30 is Crucial for Antigen-induced Death of Developing T Cells" <u>Cold Spring Harbor Laboratory Symposium on Programmed Cell Death</u> (Abstr. No. 10) (1995)
	* 59	Aplin et al., "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids" <u>CRC Crit. Rev. Biochem.</u> 10(4):259-306 (1981)
	* 60	Ashkenazi and Chamow, "Immunoadhesins: An Alternative to Human Monoclonal Antibodies" <u>Methods: A Companion to Methods in Enzymology</u> 8:104-115 (1995)
	* 61	Ashkenazi et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin" <u>Proc. Natl. Acad. Sci.</u> 88:10535-10539 (Dec 1991)
	* 62	<u>Autologous Bone Marrow Transplantation: Proceedings of the Third International Symposium</u> , Dickey et al., University of Texas M.D. Anderson Hospital (1987)
	* 63	Baldwin, "The NF- $\kappa$ B and I $\kappa$ B Proteins: New Discoveries and Insights" <u>Ann. Rev. Immunol.</u> 14:649-681 (1996)

Examiner

*C. M. K.*

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT			Applicant Ashkenazi et al.	
(Use several sheets if necessary)			Filing Date 15 Sep 1999	Group 1643 1646

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Ar	* 64	Banerji et al., "A Lymphocyte-specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes" <u>Cell</u> 33:729-740 (July 1983)
	* 65	Banner et al., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF $\beta$ Complex: Implications for TNF Receptor Activation" <u>Cell</u> 73:431-445 (1993)
	* 66	Barr et al., "Apoptosis and Its Role in Human Disease" <u>Bio/Technology</u> 12:487-493 (1994)
	* 67	Bianchi et al., "Transformation of the yeast Kluyveromyces lactis by New Vectors Derived from the 1.6 $\mu$ m Circular Plasmid pKD1" <u>Curr. Genet.</u> 12:185-192 (1987)
	* 68	"BLAST Results A-1 - A-47" (GenBank)
	* 69	"BLAST Results B-1 - B-31" (GenBank, -EST)
Ar	* 70	"BLAST Results C-1 - C-36" (Patent)
	* 71	"BLAST Results D-1 - D-40" (Dayhoff -pat)
	* 72	"BLAST Results E-1 - E-25" (Human -pat)
	* 73	"BLAST Results F-1 - F-52" (Dayhoff)
Ar	* 74	Bodmer et al., "TRAMP, a Novel Apoptosis-Mediating Receptor with Sequence Homology to Tumor Necrosis Factor Receptor 1 and Fas(Apo-1/CD95)" <u>Immunity</u> 6:79-88 (1997)
	* 75	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
	* 76	Boldin et al., "Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death" <u>Cell</u> 85:803-815 (1996)
	* 77	Boldin et al., "Self-Association of the "Death Domains" of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects" <u>Journal of Biological Chemistry</u> 270:387-391 (1995)
	* 78	Boulianne et al., "Production of functional chimaeric mouse/human antibody" <u>Nature</u> 312:643-646 (December 13, 1984)
	* 79	Bradley, "Production and Analysis of Chimaeric Mice" <u>Teratocarcinomas and Embryonic Stem Cells: A Practical Approach</u> , E. J. Robertson, ed., IRL, Oxford, Chapter 5, pps. 113-151 (1987)
	* 80	Brockhaus et al., "Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 87:3127-3131 (1990)
	* 81	Brodeur et al., "Mouse-Human Myeloma Partners for the Production of Heterohybridomas" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 51-63 (1987)
	* 82	Brojatsch et al., "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis" <u>Cell</u> 87:845-855 (Nov 29, 1996)
Ar	* 83	Bruggemann et al., "Designer Mice: The Production of Human Antibody Repertoires in Transgenic Animals" <u>Year in Immunology</u> 7:33-40 (1993)

Examiner

*John M. K.*

Date Considered

*3/12/03*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Ashkenazi et al.		
		Filing Date 15 Sep 1999	Group 4643 1648	

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Ar	* 84	Byrn et al., "Biological Properties of a CD4 Immunoadhesin" <u>Nature</u> 344:667-670 (April 12, 1990)
	* 85	Canaani et al., "Regulated Expression of Human Interferon $\beta_1$ Gene After Transduction into Cultured Mouse and Rabbit Cells" <u>Proc. Natl. Acad. Sci. USA</u> 79:5166-5170 (September 1982)
	* 86	Capon et al., "Designing CD4 Immunoadhesins for AIDS Therapy" <u>Nature</u> 337:525-531 (February 9, 1989)
	* 87	Caron et al., "Engineered humanized dimeric forms of IgG are more effective antibodies" <u>Journal of Experimental Medicine</u> 176(4):1191-1195 (Oct. 1, 1992)
	* 88	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)
Ar	* 89	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (1985)
	* 90	Chamow et al., "A Humanized Bispecific Immunoadhesin-Antibody That Retargets CD3 <sup>+</sup> Effectors to Kill HIV-1-Infected Cells" <u>Journal of Immunology</u> 153:4268-4280 (1994)
Ar	* 91	Chang et al., "Phenotypic Expression in <i>E. coli</i> of a DNA Sequence Coding for Mouse Dihydrofolate Reductase" <u>Nature</u> 275:617-624 (October 19, 1978)
	* 92	Chaudhary et al., "Death Receptor 5, a New Member of the TNFR Family, and DR4 Induce FADD-Dependent Apoptosis and Activate the NF- $\kappa$ B Pathway" <u>Immunity</u> 7:821-830 (1997)
CL		Chemotherapy Service Ed., M.C. Perry, Baltimore, MD:Williams & Wilkins (1992)
	* 93	
Ar	* 94	Chinnaiyan and Dixit, "The Cell-Death Machine" <u>Current Biology</u> 6:555-562 (1996)
	* 95	Chinnaiyan et al., "FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis" <u>Cell</u> 81:505-512 (1995)
	* 96	Chinnaiyan et al., "FADD/MORT1 Is a Common Mediator of CD95 (Fas/APO-1) and Tumor Necrosis Factor Receptor-induced Apoptosis" <u>Journal of Biological Chemistry</u> 271:4961-4965 (1996)
	* 97	Chinnaiyan et al., "Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death" <u>Science</u> 275:1122-1126 (1997)
	* 98	Chinnaiyan et al., "Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95" <u>Science</u> 274:990-992 (1996)
	* 99	Chothia and Lesk, "Canonical structures for the hypervariable regions of immunoglobulins" <u>J. Mol. Biol.</u> 196(4):901-917 (1987)
	*100	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" <u>Journal Mol. Biol.</u> 105:1-14 (1976)
	*101	Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" <u>Methods in Enzymology</u> 288:15-27 (1997)
Ar	*102	Cleveland and Ihle, "Contenders in FasL/TNF Death Signaling" <u>Cell</u> 81:479-482 (1995)
	*103	Cohen, "Programmed Cell Death in the Immune System" <u>Advances in Immunol.</u> 50:55-85 (1991)

Examiner

*John N. Ky*

Date Considered

*3/12/03*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710
<p style="text-align: center;">JAN 27 2000 P 37 LIST OF DISCLOSURES MADE BY APPLICANT (Use several sheets if necessary)</p>		Applicant Ashkenazi et al.		
		Filing Date 15 Sep 1999	Group 1643 1646	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
<i>Cr</i>	*104	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , Reisfeld et al., New York:Alan R. Liss, Inc. pps. 77-96 (1985)		
<i>Cr</i>	*105	Creighton, "Protein Biosynthesis" <u>Proteins: Structures and Molecular Principles</u> , San Francisco:W.H. Freeman & Co. pps. 79-86 (1983)		
	*106	Darzynkiewicz et al., "Assays of Cell Viability: Discrimination of Cells Dying by Apoptosis" <u>Methods in Cell Biol.</u> 41:15-38 (1994)		
<i>Ar</i>	*107	David et al., "Protein Iodination with Solid State Lactoperoxidase" <u>Biochemistry</u> 13(5):1014-1021 (1974)		
	*108	Dealtry et al., "DNA Fragmentation and Cytotoxicity Caused by Tumor Necrosis Factor is Enhanced by Interferon- $\gamma$ " <u>European Journal of Immunology</u> 17:689-693 (1987)		
	*109	deBoer et al., "The TAC Promoter: A functional Hybrid Derived From the TRP and LAC Promoters" <u>Proc. Natl. Acad. Sci. USA</u> 80:21-25 (1983)		
	*110	Degli-Esposti et al., "Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family" <u>Journal of Experimental Medicine</u> 186(7):1165-1170 (Oct 6, 1997)		
	*111	Depicker et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence" <u>J. Mol. Appl. Gen.</u> 1:561-573 (1982)		
	*112	Dieffenbach et al., <u>PCR Primer: A Laboratory Manual</u> , Cold Spring Harbor Laboratory Press pps. 1-16;133-142 (1995)		
<i>V</i>	*113	Dolby et al., "Cloning and partial nucleotide sequence of human immunoglobulin $\mu$ chain cDNA from B cells and mouse-human hybridomas" <u>Proc. Natl. Acad. Sci. USA</u> 77(10):6027-6031 (1980)		
<i>Cr</i>	*114	Duksin et al., "Relationship of the Structure and Biological Activity of the Natural Homologues of Tunicamycin" <u>Journal of Biological Chemistry</u> 257:3105-3109 (1982)		
	*115	Eck and Sprang, "The structure of tumor necrosis factor- $\alpha$ at 2.6 Å resolution" <u>Journal of Biological Chemistry</u> 264(29):17595-17604 (1989)		
	*116	Eck et al., "The Structure of Human Lymphotoxin (Tumor Necrosis Factor- $\beta$ ) at 1.9-Å Resolution" <u>J. Bio. Chem.</u> 267:2119-2122 (1992)		
<i>Cr</i>	*117	Edge et al., "Deglycosylation of glycoproteins by trifluoromethanesulfonic acid" <u>Analytical Biochemistry</u> 118:131-137 (1981)		
	*118	Ellis, "Recognition of HLA-B27 and Related Antigen by a Monoclonal Antibody" <u>Human Immunology</u> 5:49-59 (1982)		
	*119	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand Trail" <u>Journal of Interferon and Cytokine Research</u> (Abstract No. 2.17 from the 7th Intl. Tumor Necrosis Factor Congress May 17-21) 18(5):A-47 (May 1998)		
	*120	Enari et al., "Involvement of an ICE-like protease in Fas-mediated Apoptosis" <u>Nature</u> 375:78-81 (1995)		
<i>Cent</i>	*121	Evan et al., "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product" <u>Molecular &amp; Cellular Biology</u> 5:3610-3616 (1985)		
	*122	Fadok et al., "Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages" <u>J. Immunol.</u> 148:2207-2216 (1992)		
<i>Cr</i>	*123	Falkner and Zachau, "Expression of mouse immunoglobulin genes in monkey cells" <u>Nature</u> 298:286-288 (1982)		
Examiner	<i>Chen M. Key</i>		Date Considered 3/12/03	
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. 09/396,710
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)				Applicant Ashkenazi et al. Filing Date 15 Sep 1999	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
<i>Cur</i>	*124	Field et al., "Purification of a RAS-Responsive Adenylyl Cyclase Complex from <i>Saccharomyces cerevisiae</i> by Use of an Epitope Addition Method" <i>Molecular &amp; Cellular Biology</i> 8:2159-2165 (1988)			
<i>Chr</i>	*125	Fiers et al., "Complete Nucleotide Sequence of SV40 DNA" <i>Nature</i> 273:113-120 (May 11, 1978)			
	*126	Fishwild et al., "High-avidity human IgG <sub>1</sub> -monoclonal antibodies from a novel strain of minilocus transgenic mice" <i>Nature Biotechnology</i> 14(7):845-851 (Jul 1996)			
<i>Cole</i>	*127	Fleer et al., "Stable Multicopy Vectors for High-Level Secretion of Recombinant Human Serum Albumin by Kluyveromyces Yeasts" <i>Bio/Technology</i> 9:968-975 (1991)			
	*128	Fraser and Evan, "A License to Kill" <i>Cell</i> 85:781-784 (1996)			
	*129	Gelb et al., "Pycnodynatosis: Refined Linkage and Radiation Hybrid Analyses Reduce the Critical Region to 2 cM at 1q21 and Map Two Candidate Genes" <i>Human Genet.</i> 98:141-144 (1996)			
	*130	Gething et al., "Cell-surface Expression of Influenza Haemagglutinin from a Cloned DNA Copy of the RNA Gene" <i>Nature</i> 293:620-625 (October 22, 1981)			
	*131	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells" <i>Proc. Natl. Acad. Sci. USA</i> 94(14):7509-7514 (Jul 8, 1997)			
	*132	Glassy, M., "Production methods for generating human monoclonal antibodies" <i>Human Antibodies &amp; Hybridomas</i> 4(4):154-165 (Oct 1993)			
	*133	Goding, "Production of Monoclonal Antibodies" <i>Monoclonal Antibodies: Principles and Practice</i> , Academic Press, pps. 59-103 (1986)			
	*134	Goeddel et al., "Direct Expression in <i>Escherichia coli</i> of a DNA Sequence Coding for Human Growth Hormone" <i>Nature</i> 281:544-548 (October 18, 1979)			
	*135	Goeddel et al., "Synthesis of Human Fibroblast Interferon by <i>E. coli</i> " <i>Nucleic Acids Research</i> 8(18):4057-4074 (1980)			
	*136	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor" <i>Molecular &amp; Cellular Biology</i> 11:3020-3026 (1991)			
	*137	Gorman et al., "The Rous Sarcoma Virus Long Terminal Repeat is a Strong Promoter When Introduced into a Variety of Eukaryotic Cells by DNA-Mediated Transfection" <i>Proc. Natl. Acad. Sci. USA</i> 79:6777-6781 (November 1982)			
	*138	Gough et al., "Molecular cloning of seven mouse immunoglobulin κ chain messenger ribonucleic acids" <i>Biochemistry</i> 19:2702-2710 (1980)			
	*139	Graham et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA" <i>Virology</i> 52:456-467 (1973)			
	*140	Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" <i>J. Gen. Virol.</i> 36:59-72 (1977)			
	*141	Gray et al., "Expression of Human Immune Interferon cDNA in <i>E. coli</i> and Monkey Cells" <i>Nature</i> 295:503-508 (February 11, 1982)			
	*142	Greenaway et al., "Human Cytomegalovirus DNA: BamHI, EcoRI and PstI Restriction Endonuclease Cleavage Maps" <i>Gene</i> 18:355-360 (1982)			
<i>Chr</i>	*143	Gruss and Dower, "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas" <i>Blood</i> 85:3378-3404 (1995)			
Examiner	<i>Clay M. K.</i>			Date Considered <i>3/12/03</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		<b>Applicant</b> Ashkenazi et al.		
		Filing Date 15 Sep 1999	Group 1643 1646	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
<i>CW</i>	*144	Hale et al., "Demonstration of in vitro and in vivo efficacy of two biologically active human soluble TNF receptors expressed in <i>E. coli</i> " <i>J. Cell. Biochem.</i> (abstract only Supplement 15F; P 424) pps. 113 (1991)		
	*145	Hess et al., "Cooperation of Glycolytic Enzymes" <i>Advances in Enzyme Regulation</i> , George Weber, New York: Pergamon Press Vol. 7:149-167 (1968)		
	*146	Hitzeman et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique" <i>Journal of Biological Chemistry</i> 255(24):12073-12080 (December 25, 1980)		
	*147	Hohmann et al., "Two different cell types have different major receptors for human tumor necrosis factor (TNF $\alpha$ )" <i>Journal of Biological Chemistry</i> 264(25):14927-14934 (1989)		
	*148	Holland et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase" <i>Biochemistry</i> 17(23):4900-4907 (1978)		
	*149	Hoogenboom and Winter, "By-passing immunisation: human antibodies from synthetic repertoires of germline V <sub>H</sub> gene segments rearranged in vitro" <i>J. Mol. Biol.</i> 227:381-388 (1992)		
	*150	Hopp et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification" <i>Bio/Technology</i> 6:1204-1210 (1988)		
	*151	Hsiao et al., "High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4 Gene" <i>Proc. Natl. Acad. Sci. USA</i> 76:3829-3833 (1979)		
	*152	Hsu et al., "TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways" <i>Cell</i> 84:299-308 (1996)		
	*153	Hunter et al., "Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity" <i>Nature</i> 194:495-496 (1962)		
	*154	Iliades et al., "Triabodies: single chain Fv fragments without a linker form trivalent trimers" <i>FEBS Letters</i> 409(3):437-441 (Jun 16, 1997)		
	*155	Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" <i>Cell</i> 66:233-243 (1991)		
	*156	Jakobovits et al., "Analysis of Homozygous Mutant Chimeric Mice: Deletion of the Immunoglobulin Heavy-Chain Joining Region Blocks B-cell Development and Antibody Production" <i>Proc. Natl. Acad. Sci. USA</i> 90:2551-2555 (March 1993)		
	*157	Jakobovits et al., "Germ-line Transmission and Expression of a Human-Derived Yeast Artificial Chromosome" <i>Nature</i> 362:255-258 (March 18, 1993)		
	*158	Johnson et al., "Expression and Structure of the Human NGF Receptor" <i>Cell</i> 47:545-554 (November 21, 1986)		
	*159	Jones et al., "Replacing the Complementarity-determining Regions in a Human Antibody with Those From a Mouse" <i>Nature</i> 321:522-525 (May 29, 1986)		
*160	Jones, E., "Proteinase Mutants of <i>Saccharomyces Cerevisiae</i> " <i>Genetics</i> 85(1):23-33 (1977)			
161	Jones, Y., "Cytokine Receptor Complexes Verses Cell Adhesion Interactions - Upping the Affinity" (Abstract no. M11.0A.002 presented at the XVIIIth IUCr Congress & General Assembly held in Glasgow, Scotland on August 4th-13th, 1999.) pps. 133			
*162	Keown et al., "Methods for Introducing DNA into Mammalian Cells" <i>Methods in Enzymology</i> 185:527-537 (1990)			
<i>CW</i>	*163	Kingsman et al., "Replication in <i>Saccharomyces Cerevisiae</i> of Plasmid pBR313 Carrying DNA from the Yeast trp <sub>L</sub> Region" <i>Gene</i> 7:141-152 (1979)		
Examiner <i>Chen H</i>	Date Considered <i>3/12/03</i>			
<small>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		<b>Applicant</b> Ashkenazi et al. <b>Filing Date</b> 15 Sep 1999		
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
<i>CP</i>	*164	Kitson et al., "A Death-Domain-Containing Receptor that Mediates Apoptosis" <u>Nature</u> 384:372-375 (1996)		
	*165	Kohler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)		
<i>CR</i>	*166	Kohno et al., "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor" <u>Proc. Natl. Acad. Sci. USA</u> 87:8331-8335 (1990)		
	*167	<del>Koopman et al., "Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis" <u>Blood</u> 84:1415-1420 (1994)</del>		
<i>CR</i>	*168	Kortt et al., "Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer" <u>Protein Engineering</u> 10(4):423-433 (Apr 1997)		
	*169	Kozak, "An analysis of vertebrate mRNA sequences: intimations of translational control" <u>Journal of Cell Biology</u> 115:887-903 (1991)		
<i>DR</i>	*170	Kozbor et al., "A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies" <u>The Journal of Immunology</u> 133(6):3001-3005 (1984)		
	*171	Krammer et al., "Regulation of Apoptosis in the Immune System" <u>Curr. Op. Immunol.</u> 6:279-289 (1994)		
<i>DR</i>	*172	<del>Kyriakis et al., "Sounding the Alarm: Protein Kinase Cascades Activated by Stress and Inflammation" <u>Journal of Biological Chemistry</u> 271:24313-24316 (1996)</del>		
	*173	Laimins et al., "Osmotic Control of kdp Operon Expression in <i>Escherichia Coli</i> " <u>Proc. Natl. Acad. Sci. USA</u> 78(1):464-468 (Jan 1981)		
<i>CR</i>	*174	Lesslauer et al., "Bioactivity of recombinant human TNF receptor fragments" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P432) p. 115 (1991)		
	*175	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific" <u>Proc. Natl. Acad. Sci. USA</u> 88:2830-2834 (1991)		
<i>CR</i>	*176	Li et al., "Targeted mutation of the DNA methyltransferase gene results in embryonic lethality" <u>Cell</u> 69:915-926 (1992)		
	*177	LIFESEQ Database EST-Sequence-Reference "1" <b>DO NOT PRINT</b>		
<i>CR</i>	*178	LIFESEQ Database EST-Sequence-Reference "2" <b>DO NOT PRINT</b>		
	*179	<del>Liu et al., "Dissection of TNF Receptor 1 Effector Functions: JNK Activation is not Linked to Apoptosis While NF-<math>\kappa</math>B Activation Prevents Cell Death" <u>Cell</u> 87:565-576 (1996)</del>		
<i>CR</i>	*180	Loetscher et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor" <u>Cell</u> 61:351-359 (April 20, 1990)		
	*181	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" <u>Bio/Technology</u> 6:47-55 (1988)		
<i>CR</i>	*182	Lusky et al., "Bovine Papilloma Virus Contains an Activator of Gene Expression at the Distal End of the Early Transcription Unit" <u>Molecular &amp; Cellular Biology</u> 3(6):1108-1122 (June 1983)		
	*183	Lutz-Freyermuth et al., "Quantitative Determination That One of Two Potential RNA-binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-loop II of U1 RNA" <u>Proc. Natl. Acad. Sci. USA</u> 87:6393-6397 (1990)		
Examiner <i>Paul M. B.</i>	Date Considered <i>3/12/03</i>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT		Applicant Ashkenazi et al.		
(Use several sheets if necessary)		Filing Date 15 Sep 1999	Group 1643 1646	

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

All	*184	MacFarlane et al., "Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL" <u>Journal of Biological Chemistry</u> 272(41):25417-25420 (Oct 10, 1997)
	*185	MacKay et al., "Differential Responses of Fibroblasts from Wild-Type and TNF-R55-Deficient Mice to Mouse and Human TNF- $\alpha$ Activation" <u>J. Immunol.</u> 153:5274-5284 (1994)
	*186	Maeda et al., "Production of Human $\alpha$ -interferon in Silkworm Using a Baculovirus Vector" <u>Nature</u> 315:592-594 (June 13, 1985)
	*187	Mage et al., "Preparation of Fab and F(ab') <sub>2</sub> Fragments from Monoclonal Antibodies" <u>Monoclonal Antibody Production Techniques and Applications</u> , New York:Marcel Dekker, Inc. pps. 79-97 (1987)
V CWR	*188	Mallett et al., "Characterization of the MRC OX40 Antigen of Activated CD4 Positive T Lymphocytes - a Molecule Related to Nerve Growth Factor Receptor" <u>EMBO Journal</u> 9:1063-1068 (1990)
	*189	<u>Mammalian Cell Biotechnology: A Practical Approach</u> , M. Butler, ed., IRL Press (1991)
All	*190	Mansour et al., "Disruption of the Proto-oncogene int-2 in Mouse Embryo-derived Stem Cells: a General Strategy for Targeting Mutations to Non-selectable Genes" <u>Nature</u> 336:348-352 (1988)
	*191	Mantel et al., "Rabbit $\beta$ -globin mRNA Production in Mouse L Cells Transformed with Cloned Rabbit $\beta$ -globin Chromosomal DNA" <u>Nature</u> 281:40-46 (September 6, 1979)
	*192	Marks et al., "By-passing immunization: human antibodies from V-gene libraries displayed on phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*193	Marsters et al., "A Novel Receptor for Apo2L/TRAIL Contains a Truncated Death Domain" <u>Current Biology</u> 7:1003-1006 (1997)
	*194	Marsters et al., "Activation of Apoptosis by Apo-2 Ligand is Independent of FADD but Blocked by CrmA" <u>Current Biology</u> 6(6):750-752 (1996)
	*195	Marsters et al., "Apo-3, a New Member of the Tumor Necrosis Factor Receptor Family, Contains a Death Domain and Activates Apoptosis and NF- $\kappa$ B" <u>Curr. Biol.</u> 6(12):1669-1676 (1996)
	*196	Marsters et al., "Herpesvirus Entry Mediator, A Member of the Tumor Necrosis Factor (TNFR) Family, Interacts with Members of the TNFR-associated Factor Family and Activates the Transcription Factors NF- $\kappa$ B and AP-1" <u>Journal of Biological Chemistry</u> 272(22):14029-14032 (1997)
All	*197	Marsters et al., "Interferon $\gamma$ Signals Via a High-Affinity Multisubunit Receptor Complex That Contains Two Types of Polypeptide Chain" <u>Proc. Natl. Acad. Sci. USA</u> 92:5401-5405 (1995)
	*198	Martin et al., "Cell-free Reconstitution of Fas-, UV Radiation- and Ceramide-induced Apoptosis" <u>EMBO Journal</u> 14(2T):5191-5200 (1995)
All	*199	Martin et al., "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K <sup>+</sup> Channel Currents" <u>Science</u> 255:192-194 (1992)
	*200	Mather et al., "Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium" <u>Annals N.Y. Acad. Sci.</u> 383:44-68 (1982)
	*201	Mather et al., "Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines" <u>Biol. Reprod.</u> 23:243-252 (1980)
	*202	Maxam et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages" <u>Methods in Enzymology</u> 65:499-560 (1980)
All	*203	McCafferty et al., "Phage antibodies: filamentous phage displaying antibody variable domains" <u>Nature</u> 348:552-554 (1990)

Examiner

*Ray M. K.*

Date Considered

*3/12/03*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 15 Sep 1999	Group 1643/646
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
*204	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" <u>Nature Genetics</u> 15:146-156 (Feb 1997)				
*205	Messing et al., "A System for Shotgun DNA Sequencing" <u>Nucleic Acids Research</u> 9(2):309-321 (1981)				
*206	Miller et al., "An Insect Baculovirus Host-Vector System for High-Level Expression of Foreign Genes" <u>Genetic Engineering</u> , Setlow et al., Plenum Publishing Vol. 8:277-298 (1986)				
*207	Milstein et al., "Hybrid Hybridomas and Their Use in Immunohistochemistry" <u>Nature</u> 305:537-540 (1983)				
*208	Montgomery et al., "Herpes Simplex Virus-1 Entry into Cells Mediated by a Novel Member of the TNF/NGF Receptor Family" <u>Cell</u> 87(3):427-436 (1996)				
*209	Moore et al., "Apoptosis in CHO Cell Batch Cultures: Examination by Flow Cytometry" <u>Cytotechnology</u> 17:1-11 (1995)				
*210	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Antigen-binding Domains with Human Constant Region Domains" <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November 1984)				
*211	Morrison et al., "Transfer and expression of immunoglobulin genes" <u>Annual Review of Immunology</u> 2:239-256 (1984)				
*212	Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies" <u>Science</u> 229:1202-1207 (September 20, 1985)				
*213	Mulligan et al., "Expression of a Bacterial Gene in Mammalian Cells" <u>Science</u> 209:1422-1427 (Sep 1980)				
*214	Munro, "Uses of chimaeric antibodies" <u>Nature</u> 312:597 (1984)				
*215	Munson et al., "LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems" <u>Analytical Biochemistry</u> 107:220-239 (1980)				
*216	Muzio et al., "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex" <u>Cell</u> 85:817-827 (1996)				
*217	Nagata et al., "The Fas Death Factor" <u>Science</u> 267:1449-1456 (1995)				
*218	Nagata, "Apoptosis by Death Factor" <u>Cell</u> 88:355-365 (1997)				
*219	NCBI/GenBank EST; Locus AA223122: (computer printout attached)				
*220	NCBI/GenBank EST; Locus AA232440: (computer printout attached)				
*221	NCBI/GenBank EST; Locus HS75A7R: (computer printout attached)				
*222	Neuberger et al., "Recombinant Antibodies Possessing Novel Effector Functions" <u>Nature</u> 312:604-608 (December 13, 1984)				
*223	Nophar et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor" <u>EMBO Journal</u> 9:3269-3278 (1990)				
Examiner <i>Chen M. K.</i>	Date Considered <i>3/12/03</i>				
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Ashkenazi et al.		
		Filing Date 15 Sep 1999	Group 1643/646	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>				
*224	Nygren, H., "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents" <u>The Journal of Histochemistry and Cytochemistry</u> 30(5):407-412 (1982)			
*225	Olsson and Kaplan, "Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5429-5431 (1980)			
*226	Osborne et al., "Transcription Control Region Within the Protein-coding Portion of Adenovirus E1A Genes" <u>Molecular &amp; Cellular Biology</u> 4(7):1293-1305 (July 1984)			
*227	Paborsky et al., "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen" <u>Protein Eng.</u> 3(6):547-553 (1990)			
*228	Pain et al., "Preparation of Protein A-Peroxidase Monoconjugate Using a Heterobifunctional Reagent, and its Use in Enzyme Immunoassays" <u>Journal of Immunological Methods</u> 40:219-230 (1981)			
*229	Pan et al., "An Antagonist Decoy Receptor and a Death-domain Containing Receptor for TRAIL" <u>Science</u> 277:815-818 (1997)			
*230	Pan et al., "The Receptor for the Cytotoxic Ligand TRAIL" <u>Science</u> 276:111-113 (1997)			
*231	Pavlakis et al., "Expression of Two Human Growth Hormone Genes in Monkey Cells Infected by Simian Virus 40 Recombinants" <u>Proc. Natl. Acad. Sci. USA</u> 78(12):7398-7402 (December 1981)			
*232	Peetre et al., "A tumor necrosis factor binding protein is present in human biological fluids" <u>Eur. J. Haematol.</u> 41:414-419 (1988)			
*233	Pennica et al., "Human Tumour Necrosis Factor: Precursor Structure, Expression and Homology to Lymphotoxin" <u>Nature</u> 312:724-729 (1984)			
*234	Peppel and Beutler, "Chimaeric TNF-Receptor-IgG Molecule Acts as Soluble Inhibitor of TNF Mediated Cytotoxicity" <u>J. Cell. Biochem.</u> (abstract only, Supplement 15F; P439) p. 118 (1991)			
*235	Peterson, N., "Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies" <u>Laboratory Animal Science</u> 46(1):8-14 (Feb. 1996)			
*236	Pitti et al., "Induction of Apoptosis by Apo-2 Ligand; a New Member of the Tumor Necrosis Factor Cytokine Family" <u>Journal of Biological Chemistry</u> 271:12687-12690 (1996)			
*237	Presta et al., "Humanization of an Antibody Directed Against IgE" <u>J. Immunol.</u> 151(5):2623-2632 (September 1, 1993)			
*238	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)			
*239	Radeke et al., "Gene transfer and molecular cloning of the rat nerve growth factor receptor" <u>Nature</u> 325:593-597 (February 12, 1987)			
*240	Raff, "Social Controls on Cell Survival and Cell Death" <u>Nature</u> 356:397-400 (1992)			
*241	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds To The p55 TNF Receptor Death Domain" <u>Euro. Cytokine Network</u> (abstract No. 82) 7:210 (April-Jun 1996)			
*242	Raven et al., "Cloning and Functional Analysis of a Novel Protein Which Binds to the p55 TNF Receptor Death Domain" <u>Programmed Cell Death Meeting</u> (abstract only) pps. 127 (20-24 September 1995)			
*243	Ray et al., "Viral Inhibition of Inflammation: Cowpox Virus Encodes an Inhibitor of the Interleukin-1 $\beta$ Converting Enzyme" <u>Cell</u> 69:597-604 (May 15, 1992)			
Examiner <i>Clara A. Kuf</i>			Date Considered <i>5/12/03</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 15 Sep 1999	Group 1643 1646
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
*244	Remington's Pharmaceutical Sciences, Oslo et al., eds., 16th edition, Mack Publishing Co. (1980)				
*245	Reyes et al., "Expression of Human $\beta$ -interferon cDNA Under the Control of a Thymidine Kinase Promoter from Herpes Simplex Virus" <u>Nature</u> 297:598-601 (June 17, 1982)				
*246	Rice and Baltimore, "Regulated expression of an immunoglobulin $\kappa$ gene introduced into a mouse lymphoid cell line" <u>Proc. Natl. Acad. Sci. USA</u> 79:7862-7865 (1982)				
*247	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)				
*248	Rothe et al., "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor" <u>Cell</u> 78:681-692 (1994)				
*249	Sachs et al., "Control of Programmed Cell Death in Normal and Leukemic Cells: New Implications for Therapy" <u>Blood</u> 82:15-21 (1993)				
*250	Sambrook et al. <u>Molecular Cloning: A Laboratory Manual</u> , Second edition, New York: Cold Spring Harbor Laboratory Press (1989)				
*251	Schall et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor" <u>Cell</u> 61:361-370 (April 20, 1990)				
*252	Schmid et al., "DNA Fragmentation: Manifestation of Target Cell Destruction Mediated by Cytotoxic T-cell Lines, Lymphotoxin-secreting Helper T-cell Clones, and Cell-free Lymphotoxin-containing Supernatant" <u>Proc. Natl. Acad. Sci. USA</u> 83:1881-1885 (1986)				
*253	Schneider et al., "Characterization of two receptors for TRAIL" <u>FEBS Letters</u> 416:329-334 (1997)				
*254	Screaton et al., "TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL" <u>Current Biology</u> 7:693-696 (1997)				
*255	Seckinger et al., "Purification and biologic characterization of a specific tumor necrosis factor $\alpha$ Inhibitor" <u>Journal of Biological Chemistry</u> 264:11966-11973 (1989)				
*256	Sharon et al., "Expression of a V <sub>H</sub> C <sub>K</sub> chimaeric protein in mouse myeloma cells" <u>Nature</u> 309:364-367 (1984)				
*257	Shaw et al., "A General Method for the Transfer of Cloned Genes to Plant Cells" <u>Gene</u> 23:315-330 (1983)				
*258	Sheridan et al., "Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors" <u>Science</u> 277:818-821 (1997)				
*259	Shopes, "A genetically engineered human IgG mutant with enhanced cytolytic activity" <u>Journal of Immunology</u> 148(9):2918-2922 (May 1, 1992)				
*260	Siebenlist et al., "E. Coli RNA Polymerase Interacts Homologously with Two Different Promoters" <u>Cell</u> 20:269-281 (June 1980)				
*261	Simonet et al., "Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density" <u>Cell</u> 89:309-319 (Apr 18, 1997)				
*262	Sims et al., "A Humanized CD18 Antibody Can Block Function Without Cell Destruction" <u>The Journal of Immunology</u> 151(4):2296-2308 (Aug 1993)				
Ar	Skinner et al., "Use of the Glu-Glu-Phe C-terminal Epitope for Rapid Purification of the Catalytic Domain of Normal and Mutant ras GTPase-activating Proteins" <u>Journal of Biological Chemistry</u> 266:14163-14166 (1991)				
Examiner <i>Cler M. B.</i>			Date Considered <i>3/12/03</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT				Applicant Ashkenazi et al.	
(Use several sheets if necessary)				Filing Date 15 Sep 1999	Group 1643/646
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
Pur	*264	Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins" <u>Science</u> 248:1019-1023 (May 25, 1990)			
	*265	Smith et al., "T2 Open reading frame from the shope fibroma virus encodes a soluble form of the TNF receptor" <u>Biochem. &amp; Biophys. Res. Comm.</u> 176:335-342 (1991)			
	*266	Smith et al., "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death" <u>Cell</u> 76:959-962 (1994)			
	*267	Sojar et al., "A Chemical Method for the Deglycosylation of Proteins" <u>Archives of Biochemistry &amp; Biophysics</u> 259(1):52-57 (1987)			
	*268	Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter" <u>J. Molec. Appl. Genet.</u> 1:327-341 (1982)			
	*269	Stamenkovic et al., "A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas" <u>EMBO Journal</u> 8(5):1403-1410 (1989)			
	*270	Steinitz et al., "EB virus-induced B lymphocyte cell lines producing specific antibody" <u>Nature</u> 269(5627):420-422 (Sep 29, 1977)			
	*271	Steller, "Mechanisms and Genes of Cellular Suicide" <u>Science</u> 267:1445-1449 (1995)			
	*272	Stevenson et al., "A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge" <u>Anti-Cancer Drug Design</u> 3(4):219-230 (Mar 1989)			
	*273	Stinchcomb et al., "Isolation and Characterisation of a Yeast Chromosomal Replicator" <u>Nature</u> 282:39-43 (November 1, 1979)			
	*274	Suda et al., "Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the Tumor Necrosis Factor Family" <u>Cell</u> 75:1169-1178 (1993)			
	*275	Sugden et al., "A Vector that Replicates as a Plasmid and Can Be Efficiently Selected in B-Lymphoblasts Transformed by Epstein-Barr Virus" <u>Molecular &amp; Cellular Biology</u> 5:410-413 (1985)			
	*276	Suresh et al., "Bispecific Monoclonal Antibodies from Hybrid Hybridomas" <u>Methods in Enzymology</u> 121:210-228 (1986)			
	*277	Suva et al., "A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression" <u>Science</u> 237(4817):893-896 (Aug. 1987)			
	*278	Takao et al., "Novel DNA Polymorphism in the Mouse Tumor Necrosis Factor Receptors Type 1 and Type 2" <u>Immunogenetics</u> 37:199-203 (1993)			
	*279	Tartaglia et al., "A novel domain within the 55kd TNF receptor signals cell death" <u>Cell</u> 74(5):845-853 (1993)			
	*280	Tewari et al., "Fas- and Tumor Necrosis Factor-induced Apoptosis Is Inhibited by the Poxvirus crmA Gene Product" <u>Journal of Biological Chemistry</u> 270:3255-3260 (1995)			
	*281	Tewari et al., "Recent Advances in Tumor Necrosis Factor and CD40 Signaling" <u>Curr. Op. Genet. Develop.</u> 6:39-44 (1996)			
	*282	Tewari et al., "Yama/CPP32 $\beta$ , a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase" <u>Cell</u> 81:801-809 (1995)			
Cur	*283	Thomas et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells" <u>Cell</u> 51:503-512 (1987)			
Examiner <i>Clair M. Karp</i>				Date Considered <i>3/12/83</i>	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

P1101P2

Serial No.

09/396,710

Applicant

Ashkenazi et al.

Filing Date

15 Sep 1999

Group

1643

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RJ	*284	Thomas, P., "Hybridization of Denatured RNA and Small DNA Fragments Transferred to Nitrocellulose" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5201-5205 (September 1980)
	*285	Thompson, "Apoptosis in the Pathogenesis and Treatment of Disease" <u>Science</u> 267:1456-1462 (1995)
	*286	Thotakura et al., "Enzymatic Deglycosylation of Glycoproteins" <u>Meth. Enzymol.</u> 138:350-359 (1987)
	*287	<u>Tissue Culture</u> , Kruse and Patterson, eds., New York: Academic Press (1973)
AC	*288	Traunecker et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells" <u>EMBO Journal</u> 10(12):3655-3659 (1991)
	*289	Traunecker et al., "Highly Efficient Neutralization of HIV with Recombinant CD4-immunoglobulin Molecules" <u>Nature</u> 339:68-70 (1989)
	*290	Tschumper et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene" <u>Gene</u> 10:157-166 (1980)
	*291	Upton et al., "Myxoma virus expresses a secreted protein with homology to the tumor necrosis factor receptor gene family that contributes to viral virulence" <u>Virology</u> 184:370-382 (1991)
	*292	Upton et al., "Tumorigenic poxviruses: genomic organization and DNA sequence of the telomeric region of the shope fibroma virus genome" <u>Virology</u> 160:20-29 (1987)
	*293	Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity" <u>Proc. Natl. Acad. Sci. USA</u> 77(7):4216-4220 (July 1980)
	*294	Van den Berg et al., "Kluyveromyces as a Host for Heterologous Gene Expression: Expression and Secretion of Prochymosin" <u>Bio/Technology</u> 8:135-139 (1990)
	*295	Van Solingen et al., "Fusion of Yeast Spheroplasts" <u>J. Bact.</u> 130:946-947 (1977)
	*296	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)
	*297	Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)
	*298	Verma et al., "Rel/NF- $\kappa$ B/I $\kappa$ B Family: Intimate Tales of Association and Dissociation" <u>Genes Develop.</u> 9:2723-2735 (1995)
	*299	von Bulow et al., "NF-AT Activation Induced by a CAML-Interacting Member of the Tumor Necrosis Factor Receptor Superfamily" <u>Science</u> 278:138-141 (Oct 3, 1997)
	*300	Walczak et al., "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL" <u>EMBO Journal</u> 16(17):5386-5397 (1997)
	*301	Watanabe-Fukunaga et al., "Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen that Mediates Apoptosis" <u>Nature</u> 356:314-317 (1992)
	*302	Welcher et al., "Nerve growth factor binding domain of the nerve growth factor receptor" <u>Proc. Natl. Acad. Sci. USA</u> 88:159-163 (1991)
CR	*303	Wells et al., "Cassette Mutagenesis: an Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985)

Examiner

*Clara M. B.*

Date Considered

*3/12/03*

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1101P2	Serial No. 09/396,710	
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)			Applicant Ashkenazi et al.		
			Filing Date 15 Sep 1999	Group 1643 1646	
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>					
 <i>Mr</i>  <i>Dr</i>	*304	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin" <u>Philos. Trans. R. Soc. London Ser A</u> 317:415-423 (1986)			
	*305	Wiley et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis" <u>Immunity</u> 3:673-682 (1995)			
	*306	Wolff et al., "Monoclonal antibody homodimers: enhanced antitumor activity in nude mice" <u>Cancer Research</u> 53(11):2560-2565 (Jun 1, 1993)			
	*307	Wong et al., "TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells" <u>Journal of Biological Chemistry</u> 272(40):25190-25194 (Oct 3, 1997)			
	*308	Wu et al., "KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene" <u>Nature Genetics</u> 17:141-143 (October 1997)			
	*309	Yan and Chao, "Disruption of Cysteine-rich repeats of the p75 nerve growth factor receptor leads to loss of ligand binding" <u>Journal of Biological Chemistry</u> 266:12099-12104 (1991)			
	*310	Yaniv, M., "Enhancing Elements for Activation of Eukaryotic Promoters" <u>Nature</u> 297(6):17-18 (May 1982)			
	*311	Yonehara et al., "A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor" <u>Journal of Experimental Medicine</u> 169:1747-1756 (1989)			
	*312	Zheng et al., "Induction of Apoptosis in Mature T Cells by Tumor Necrosis Factor" <u>Nature</u> 377:348-351 (1995)			
	*313	Zola, "Using Monoclonal Antibodies: Soluble Antigens" <u>Monoclonal Antibodies: A Manual of Techniques</u> , CRC Press, Chapter 6, pps. 147-158 (1987)			
	*314	Zoller et al., "Oligonucleotide-directed Mutagenesis Using M13-derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" <u>Nucl. Acids Res.</u> 10(20):6487-6500 (1982)			
Examiner <i>Clair Miller</i>		Date Considered 3/12/03			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce		Atty Docket No.		Serial No.	
		Patent and Trademark Office		P1101P2		09/396,710	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant			
				Ashkenazi et al.			
				Filing Date		Group	
				15 Sep 1999		1643 1646	
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
CR	1 WO 00/66156	09.11.00	PCT				
<b>OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
CR	2 Cha et al., "Crystal Structure of TRAIL-DR5 Complex Identifies a Critical Role of the Unique Frame Insertion in Conferring Recognition Specificity" <u>The Journal of Biological Chemistry, JBC Papers in Press</u> Vol. 275(40):31171-31177 (July 11, 2000)						
<span style="font-size: 2em; vertical-align: middle;">RECEIVED</span> <span style="font-size: 1em; vertical-align: middle;">TECH CENTER 1600/2900</span> <span style="font-size: 1em; vertical-align: middle;">APR 04 2001</span>							
Examiner		Date Considered					
<i>Chen M. Key</i>		3/12/03					

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 590558

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. RE9/396,710 RECEIVED TECH CENTER 1600/2900 13 MAR 2001 1:24 15
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)					

## U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
CM	1 08/799,861					13.02.97
	2 08/815,255					12.03.97
	3 08/820,364		Gearing			12.03.97
	4 08/829,536					28.03.97
	5 08/843,651		Holtzman			16.04.97
	6 08/843,652		Holtzman			16.04.97
	7 08/853,684					09.05.97
	8 08/869,852					04.06.97
	9 08/883,036					25.06.97
	10 08/916,625					31.08.97
	11 09/042,583					17.03.98
	12 09/565,009					24.05.00
	13 09/712,726		Gearing			14.11.00
	14 2002/0048566	25.04.02	El-Deiry et al.			13.09.01
	15 2002/0048785	25.04.02	Holtzman			
	16 2002/0072091	13.06.02	Ni et al.			
	17 2002/0098550	25.07.02	Ni et al.			
	18 2002/0160446	31.10.02	Holtzman			
	19 5,763,223	09.06.98	Wiley et al.			
	20 6,313,269	06.11.01	Deen et al.			
	21 6,455,262	24.09.02	Cox et al.			
	22 60/040,846					17.03.97
	23 60/041,230					14.03.97
	24 60/054,021					29.07.97
	25 60/132,498					04.05.99
	26 60/133,238					07.05.99
CM	27 60/148,939					13.08.99

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
CM	*28 510,691	28.10.92	EPO				
CM	*29 870,827	14.10.98	EPO				
CM	30 WO 00/77191		PCT				
CM	31 WO 02/053727	11.07.02	PCT				
CM	32 WO 92/01047	23.01.92	PCT				
CM	33 WO 92/20791	26.11.92	PCT				

Examiner <i>CM</i>	Date Considered <i>3/12/03</i>
--------------------	-----------------------------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P2	Serial No. 09/396,710
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.	
				Filing Date 15 Sep 1999	Group 1646

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes      No
CK	34	WO 93/00109	07.01.93	PCT			
	35	WO 93/06213	01.04.93	PCT			
	36	WO 93/11236	10.06.93	PCT			
	37	WO 93/19172	30.09.93	PCT			
	38	WO 95/01438	12.01.95	PCT			
	39	WO 95/15388	08.06.95	PCT			
	*40	WO 98/35986	20.08.98	PCT			
	*41	WO 98/41629	24.09.98	PCT			
CK	*42	WO 98/46643	22.10.98	PCT			
CK	*43	WO 99/02653	21.01.99	PCT			
	*44	WO 99/09165	25.02.99	PCT			
	*45	WO 99/11791	11.03.99	PCT			
	*46	WO 99/12963	18.03.99	PCT			

TECH CENTER 1600  
RECEIVED  
APR 1 2000  
1600/2900

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

CK	47	Carter et al., "Antibody Engineering Using Very Long Template-Assembled Oligonucleotides" <u>Methods: A Companion to Methods in Enzymology</u> 3(3):183-192 (Dec 1991)
	48	Chapman, "A Region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas" <u>B.S. Chapman/FEBS Letters</u> 374:216-220 (1995)
	49	Handbook of Monoclonal Antibodies, Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
CK	50	Hoogenboom, "Designing and optimizing library selection strategies for generating high-affinity antibodies" <u>Trends in Biotechnology</u> 15(2):62-70 (Feb 1997)
	51	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> (NIH Publn. No. 91-3242), 5th edition
CK	52	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)
	53	Neri et al., "Engineering recombinant antibodies for immunotherapy" <u>Cell Biophysics</u> 27(1):47-61 (Aug 1995)
	54	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacology of Monoclonal Antibodies: Handbook of Experimental Pharmacology.</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)
	55	Rabidezeh et al., "Induction of Apoptosis by the Low-Affinity NGF Receptor" <u>Science</u> 261:345-348 (1993)
	56	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977)
CK	57	Soderlind et al., "Phage display technology in antibody engineering: design of phagemid vectors and in vitro maturation systems" <u>Immunological Reviews</u> 130:109-124 (Dec 1992)
CK	58	Winter et al., "Making antibodies by phage display technology" <u>Annual Review of Immunology</u> 12:433-455 (1994)

Examiner <i>Chaim M. Kal</i>	Date Considered 3/12/03
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449

JUL 22 2002

PATENT &amp; TRADEMARK OFFICE

U.S. Dept. of Commerce  
Patent and Trademark OfficeAtty Docket No.  
P1101P2Serial No.  
09/396,710Applicant  
Ashkenazi et al.Filing Date  
15 Sep 1999Group  
1646

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CLW	1	6,417,328	09.07.02	Alnemri			

Examiner

*Clawther*

Date Considered

3/12/03

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.